Systemic inflammatory response induced by systemic inflammatory response
Conditions
Interventions
Control group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The original GCP trial, namely the"Clinical trial to evaluate the efficacy and safety of single-use activated leukocyte adsorbers in removing activated leukocytes from blood during cardiopulmonary bypass surgery" (Ethics approval number: 2026 Clinical Trial (Device) Approval No. 7), met the inclusion and exclusion criteria: 2.Able to understand the purpose of the study, voluntarily agree to participate, and provide signed informed consent;
Exclusion criteria
Exclusion criteria: 1. Participants in the original GCP trial, namely the "Clinical trial to evaluate the efficacy and safety of single-use activated leukocyte adsorbents in removing activated leukocytes from blood during cardiopulmonary bypass surgery" (Ethics approval number: 2026 Clinical Trial (Device) Approval No. 7), withdrew their informed consent. 2. The sample size was insufficient; 3. The samples were not stored in accordance with the required standards; 4. The participants had serious complications that affected the testing of immune cells.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune cell subset proportions and activation status; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the transcriptome and proteome of immune cells;Leukocyte phagocytic function;Concentrations of inflammation-related cytokines;Number of platelet–leukocyte aggregates (PLAs); | — |
Countries
China
Contacts
Public ContactDu Lei
West China Hospital of Sichuan University
Outcome results
None listed